Genmab A/S (GMAB) has a MoatMap StockRank of 82/100 based on Quality (64/100), Value (62/100), and Momentum (36/100) factor scores. The current signal is STRONG BUY. Genmab A/S, a biotechnology company developing innovative antibody therapeutics for cancer, represents a high-quality compounder within the defensive healthcare sector. In an environment of 'Sticky Rates', capital shifts towards resilient businesses with strong growth prospects and durable moats (patents, scientific expertise). Genmab's robust R&D pipeline and strategic partnerships provide a long reinvestment runway, offering an asymmetric opportunity as a flight-to-quality growth story often overlooked amidst broad market volatility.